Skip to main content
    I

    ImmuCell Corporation (ICCC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.42
    +0.67 (+6.23%)

    Market Cap: $97.73M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ImmuCell Corporation (ICCC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    ImmuCell reported revenue of $27.64M for the fiscal year ended Dec 31, 2025, up 4.3% from the year before. That year, net income was -$1.04M with a net margin of -3.8%, operating cash flow was $2.48M and free cash flow was $1.22M. The quarter ended Sep 30, 2026 had revenue of $8.04M and net income of $952.51K.

    Revenue and Margins

    The operating margin was 6.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.54M, a compound annual rate of 12.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$27.64M+4.3%41.4%6.0%-3.8%
    Dec 2024$26.49M+51.6%30.0%-6.2%-8.1%
    Dec 2023$17.47M-5.9%22.1%-32.9%-33.1%
    Dec 2022$18.57M-3.5%41.2%-12.4%-13.4%
    Dec 2021$19.24M+25.4%45.0%1.3%-0.4%
    Dec 2020$15.34M+11.8%44.7%-9.0%-6.7%
    Dec 2019$13.72M+24.9%49.1%-7.0%-9.4%
    Dec 2018$10.99M+5.3%47.3%-13.2%-21.1%
    Dec 2017$10.43M+9.3%50.1%-2.3%-1.6%
    Dec 2016$9.54MN/A56.8%9.3%5.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$27.64M$26.49M$17.47M$18.57M$19.24M$15.34M$13.72M$10.99M$10.43M$9.54M
    Cost of revenue$16.20M$18.55M$13.60M$10.92M$10.59M$8.48M$6.98M$5.79M$5.21M$4.12M
    Gross profit$11.45M$7.94M$3.87M$7.65M$8.66M$6.86M$6.74M$5.19M$5.22M$5.42M
    Research and development$3.04M$3.90M$4.39M$4.49M$4.17M$4.35M$3.69M$3.52M$2.05M$1.24M
    Operating income$1.65M-$1.64M-$5.75M-$2.30M$257.38K-$1.38M-$953.91K-$1.45M-$242.84K$890.20K
    Net income-$1.04M-$2.16M-$5.77M-$2.49M-$78.29K-$1.02M-$1.30M-$2.32M-$168.15K$508.45K
    EBITDA$1.76M$583.27K-$3.03M$9.11K$2.39M$1.32M$1.00M-$339.34K$465.95K$1.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$8.04M$7.19M$10.36M$7.63M$5.51M$6.44M$8.07M$7.75M$6.01M$5.47M$7.26M$5.10M
    Gross profit$3.56M$2.44M$4.66M$2.91M$2.36M$2.82M$3.35M$2.83M$1.58M$1.23M$2.30M$1.26M
    Operating income$957.77K$1.93M$1.97M-$57.96K$20.07K$569.56K$1.12M$621.39K-$574.89K-$1.39M-$300.05K-$1.00M
    Net income$952.51K$1.83M$1.94M-$2.85M-$139.75K$501.88K$1.45M$514.55K-$701.69K-$1.53M-$437.87K-$1.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $9.10M exceeded cash and equivalents by $5.29M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$42.53M$45.10M$43.81M$44.86M$44.47M$40.35M$38.69M$32.73M$34.30M$24.70M
    Current assets$16.94M$15.04M$11.47M$14.07M$16.26M$12.16M$13.19M$6.42M$7.51M$14.35M
    Cash and equivalents$3.81M$3.76M$978.74K$5.79M$10.19M$6.95M$6.29M$2.52M$3.80M$5.15M
    Total liabilities$15.48M$17.58M$18.82M$14.48M$11.89M$12.08M$9.70M$10.99M$10.70M$4.98M
    Short-term debt$1.61M$1.50M$1.43M$1.04M$812.21K$760.34K$1.27M$1.34M$316.63K$133.27K
    Long-term debt$7.49M$9.04M$10.54M$9.19M$8.33M$8.74M$7.15M$8.42M$8.64M$2.88M
    Shareholder equity$27.06M$27.52M$24.99M$30.38M$32.58M$28.27M$28.99M$21.74M$23.59M$19.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$47.96M$46.63M$44.11M$42.53M$45.73M$46.72M$45.62M$45.10M$44.45M$41.86M$43.05M$43.81M
    Total liabilities$15.18M$15.26M$14.97M$15.48M$15.93M$16.85M$16.63M$17.58M$18.04M$18.40M$18.41MN/A
    Cash and equivalents$7.91M$8.86M$6.81M$3.81M$3.89M$6.00M$4.60M$3.76M$3.81M$1.32M$960.35K$979.00K
    Shareholder equity$32.77M$31.37M$29.14M$27.06M$29.80M$29.87M$28.99M$27.52M$26.41M$23.46M$24.64MN/A
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 49.2% of operating cash flow. Share repurchases came to 5.6% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$2.48M$357.90K-$4.67M-$1.54M$954.17K$1.32M$233.51K-$373.40K$1.18M-$222.31K
    Capital expenditures$1.25M$465.73K$1.89M$3.98M$2.61M$4.07M$1.39M$2.03M$17.76M$4.05M
    Free cash flow$1.22M-$107.82K-$6.57M-$5.52M-$1.65M-$2.76M-$1.16M-$2.40M-$16.58M-$4.27M
    Share repurchases$67.88K$291.83K$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$1.21M-$461.23K-$1.89M-$3.96M-$1.60M-$2.57M-$3.40M-$1.79M-$12.27M-$4.52M
    Financing cash flow-$1.21M$2.88M$1.75M$1.11M$3.88M$1.91M$6.94M$889.62K$9.75M$8.32M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$755.91K$3.02M$3.57M$482.54K-$1.18M$1.60M$1.57M-$3.05K-$639.33K$581.78K$418.50K-$723.07K
    Capital expenditures$1.35M$733.94K$177.23K$172.31K$593.92K$155.16K$329.05K$196.22K$88.41K$110.74K$70.36K$33.78K
    Free cash flow-$589.36K$2.29M$3.40M$310.24K-$1.78M$1.45M$1.24M-$199.27K-$727.74K$471.04K$348.15K-$756.85K
    Last 12 quarters

    Frequently Asked Questions About ICCC

    What is ImmuCell's annual revenue?

    ImmuCell reported revenue of $27.64M for the fiscal year ended Dec 31, 2025.

    How fast is ImmuCell's revenue growing?

    Revenue was up 4.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.2%.

    Is ImmuCell profitable?

    No. ImmuCell reported net income of -$1.04M for the fiscal year ended Dec 31, 2025, with a net margin of -3.8%.

    How much free cash flow does ICCC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $2.48M minus capital expenditures of $1.25M produced free cash flow of $1.22M.

    How much debt does ImmuCell have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $7.49M, short-term debt of $1.61M and cash and equivalents of $3.81M.